{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T02:31:11Z","timestamp":1771036271849,"version":"3.50.1"},"reference-count":133,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2018,4,26]],"date-time":"2018-04-26T00:00:00Z","timestamp":1524700800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1038\/s41416-018-0073-2","type":"journal-article","created":{"date-parts":[[2018,4,23]],"date-time":"2018-04-23T19:23:26Z","timestamp":1524511406000},"page":"1539-1548","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Cutaneous neurofibromas in the genomics era: current understanding and open questions"],"prefix":"10.1038","volume":"118","author":[{"given":"Robert J.","family":"Allaway","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara J. C.","family":"Gosline","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"La Rosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela","family":"Knight","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annette","family":"Bakker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin","family":"Guinney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu Q.","family":"Le","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,4,26]]},"reference":[{"issue":"2","key":"73_CR1","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/ajmg.a.33139","volume":"152A","author":"D.G. Evans","year":"2010","unstructured":"Evans, D. G. et al. Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am. J. Med. Genet. A 152A, 327\u2013332 (2010).","journal-title":"American Journal of Medical Genetics Part A"},{"key":"73_CR2","doi-asserted-by":"crossref","unstructured":"Lammert, M., Friedman, J. M., Kluwe, L. & Mautner, V. F. Prevalence of neurofibromatosis 1 in German children at elementary school enrollment. Arch. Dermatol. 141, 71\u201374 (2005).","DOI":"10.1001\/archderm.141.1.71"},{"key":"73_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaad.2008.12.051","volume":"61","author":"KP Boyd","year":"2009","unstructured":"Boyd, K. P., Korf, B. R. & Theos, A. Neurofibromatosis type 1. J. Am. Acad. Dermatol. 61, 1\u201314 (2009).","journal-title":"J. Am. Acad. Dermatol."},{"key":"73_CR4","unstructured":"Friedman, J. Neurofibromatosis 1 [Internet]. Gene reviews. University of Washington. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20301288 . Accessed 6 July 2016 (2014)."},{"key":"73_CR5","unstructured":"Recklinghausen, F. von. Ueber die multiplen Fibrome der Haut und ihre Beziehung zu den multiplen Neuromen [Internet]. https:\/\/wellcomelibrary.org . Accessed 8 August 2017 (1882)."},{"key":"73_CR6","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1038\/353864a0","volume":"353","author":"MR Wallace","year":"1991","unstructured":"Wallace, M. R. et al. A de novo Alu insertion results in neurofibromatosis type 1. Nature 353, 864\u2013866 (1991).","journal-title":"Nature"},{"key":"73_CR7","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/0092-8674(90)90252-A","volume":"62","author":"D Viskochil","year":"1990","unstructured":"Viskochil, D. et al. Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus. Cell 62, 187\u2013192 (1990).","journal-title":"Cell"},{"key":"73_CR8","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/0092-8674(90)90253-B","volume":"62","author":"RM Cawthon","year":"1990","unstructured":"Cawthon, R. M. et al. A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations. Cell 62, 193\u2013201 (1990).","journal-title":"Cell"},{"key":"73_CR9","doi-asserted-by":"publisher","first-page":"e35711","DOI":"10.1371\/journal.pone.0035711","volume":"7","author":"SR Plotkin","year":"2012","unstructured":"Plotkin, S. R. et al. Quantitative assessment of whole-body tumor burden in adult patients with neurofibromatosis. PLoS ONE 7, e35711 (2012).","journal-title":"PLoS ONE"},{"key":"73_CR10","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1212\/WNL.50.6.1755","volume":"50","author":"JH Tonsgard","year":"1998","unstructured":"Tonsgard, J. H., Kwak, S. M., Short, M. P. & Dachman, A. H. CT imaging in adults with neurofibromatosis-1: frequent asymptomatic plexiform lesions. Neurology 50, 1755\u20131760 (1998).","journal-title":"Neurology"},{"key":"73_CR11","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1136\/jmg.39.5.311","volume":"39","author":"DGR Evans","year":"2002","unstructured":"Evans, D. G. R. et al. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J. Med. Genet. 39, 311\u2013314 (2002).","journal-title":"J. Med. Genet."},{"key":"73_CR12","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.1016\/j.ejca.2011.05.031","volume":"47","author":"S Ingham","year":"2011","unstructured":"Ingham, S. et al. Malignant peripheral nerve sheath tumours in NF1: improved survival in women and in recent years. Eur. J. Cancer 47, 2723\u20132728 (2011).","journal-title":"Eur. J. Cancer"},{"key":"73_CR13","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1093\/hmg\/ddp212","volume":"18","author":"A Sabbagh","year":"2009","unstructured":"Sabbagh, A. et al. Unravelling the genetic basis of variable clinical expression in neurofibromatosis 1. Hum. Mol. Genet. 18, 2768\u20132778 (2009).","journal-title":"Hum. Mol. Genet."},{"key":"73_CR14","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.ajpath.2010.10.041","volume":"178","author":"EM Jouhilahti","year":"2011","unstructured":"Jouhilahti, E.-M. et al. The development of cutaneous neurofibromas. Am. J. Pathol. 178, 500\u201355 (2011).","journal-title":"Am. J. Pathol."},{"key":"73_CR15","doi-asserted-by":"crossref","unstructured":"Peltonen, J., Jouhilahti, E.-M. & Peltonen, S. in Neurofibromatosis Type 1 (eds Upadhyaya, M. & Cooper, D.) 393\u2013403 (Springer, Berlin, Heidelberg, 2012).","DOI":"10.1007\/978-3-642-32864-0_26"},{"key":"73_CR16","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1136\/jmg.2006.045906","volume":"44","author":"RE Ferner","year":"2006","unstructured":"Ferner, R. E. et al. Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J. Med. Genet. 44, 81\u201388 (2006).","journal-title":"J. Med. Genet."},{"key":"73_CR17","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/(SICI)1096-8628(19961202)66:1<7::AID-AJMG2>3.0.CO;2-R","volume":"66","author":"L Dugoff","year":"1996","unstructured":"Dugoff, L. & Sujansky, E. Neurofibromatosis type 1 and pregnancy. Am. J. Med. Genet. 66, 7\u201310 (1996).","journal-title":"Am. J. Med. Genet."},{"key":"73_CR18","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/ajmg.1320590427","volume":"59","author":"BL Wu","year":"1995","unstructured":"Wu, B. L., Austin, M. A., Schneider, G. H., Boles, R. G. & Korf, B. R. Deletion of the entire NF1 gene detected by FISH: four deletion patients associated with severe manifestations. Am. J. Med. Genet. 59, 528\u2013535 (1995).","journal-title":"Am. J. Med. Genet."},{"key":"73_CR19","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1159\/000337548","volume":"224","author":"S Granstr\u00f6m","year":"2012","unstructured":"Granstr\u00f6m, S., Langenbruch, A., Augustin, M. & Mautner, V.-F. Psychological burden in adult neurofibromatosis type 1 patients: impact of disease visibility on body image. Dermatology 224, 160\u2013167 (2012).","journal-title":"Dermatology"},{"key":"73_CR20","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s00401-012-0954-z","volume":"123","author":"FJ Rodriguez","year":"2012","unstructured":"Rodriguez, F. J., Folpe, A. L., Giannini, C. & Perry, A. Pathology of peripheral nerve sheath tumors: diagnostic overview and update on selected diagnostic problems. Acta Neuropathol. 123, 295\u2013319 (2012).","journal-title":"Acta Neuropathol."},{"key":"73_CR21","doi-asserted-by":"crossref","unstructured":"Ruggieri, M., Upadhyaya, M., Rocco, C. Di, Gabriele, A. & Pascual-Castroviejo, I. in Neurocutaneous Disorders Phakomatoses and Hamartoneoplastic Syndromes (eds Ruggieri, M., Castroviejo, I. P. & Rocco, C. D.) 51\u2013151 (Springer, Vienna, 2008).","DOI":"10.1007\/978-3-211-69500-5_3"},{"key":"73_CR22","unstructured":"Ortiz-Hidalgo, C. & Weller, R. in Histology for Pathologists 2nd edn (ed. Sternberg, S.) 285\u2013311 (Lippincott-Raven Publishers, Philadelphia, 1997)."},{"key":"73_CR23","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1097\/01.COT.0000502634.14826.10","volume":"38","author":"LQ Le","year":"2016","unstructured":"Le, L. Q., Kesterson, R. A. & Gutmann, D. H. Defining the research landscape for dermal neurofibromas. Oncol. Times 38, 14\u201315 (2016).","journal-title":"Oncol. Times"},{"key":"73_CR24","doi-asserted-by":"crossref","first-page":"61500","DOI":"10.18632\/oncotarget.11133","volume":"7","author":"CP Liao","year":"2016","unstructured":"Liao, C.-P. et al. The role of nerve microenvironment for neurofibroma development. Oncotarget 7, 61500\u201361508 (2016).","journal-title":"Oncotarget"},{"key":"73_CR25","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.1093\/hmg\/ddl165","volume":"15","author":"FC Yang","year":"2006","unstructured":"Yang, F. C. et al. Nf1+\/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling. Hum. Mol. Genet. 15, 2421\u20132437 (2006).","journal-title":"Hum. Mol. Genet."},{"key":"73_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/srep43315","volume":"7","author":"K Choi","year":"2017","unstructured":"Choi, K. et al. An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system. Sci. Rep. 7, 43315 (2017).","journal-title":"Sci. Rep."},{"key":"73_CR27","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1097\/01.MP.0000062654.83617.B7","volume":"16","author":"T Hirose","year":"2003","unstructured":"Hirose, T. et al. Immunohistochemical demonstration of EMA\/Glut1-positive perineurial cells and CD34-positive fibroblastic cells in peripheral nerve sheath tumors. Mod. Pathol. 16, 293\u2013298 (2003).","journal-title":"Mod. Pathol."},{"key":"73_CR28","first-page":"515","volume":"3","author":"ND Riddle","year":"2010","unstructured":"Riddle, N. D., Gorden, L., Rojiani, M. V., Hakam, A. & Rojiani, A. M. CD44 and p53 immunoexpression patterns in NF1 neoplasms - indicators of malignancy and infiltration. Int. J. Clin. Exp. Pathol. 3, 515\u2013521 (2010).","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"73_CR29","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.ccr.2007.12.027","volume":"13","author":"J Wu","year":"2008","unstructured":"Wu, J. et al. Plexiform and dermal neurofibromas and pigmentation are caused by Nf1 loss in desert hedgehog-expressing cells. Cancer Cell 13, 105\u2013116 (2008).","journal-title":"Cancer Cell"},{"key":"73_CR30","doi-asserted-by":"crossref","unstructured":"Le, L. Q., Shipman, T., Burns, D. K. & Parada, L. F. Cell of origin and microenvironment contribution for NF1-associated dermal neurofibromas. Cell Stem Cell 4, 453\u2013463 (2009).","DOI":"10.1016\/j.stem.2009.03.017"},{"key":"73_CR31","unstructured":"(NHGRI) National Human Genome Research Institute. [NCT00314119] Natural History and Biology of Skin Neurofibromas in Neurofibromatosis Type 1. ClinicalTrials.gov. (2006)."},{"key":"73_CR32","unstructured":"National Cancer Institute (NCI). [NCT00924196] Natural History Study of Patients with Neurofibromatosis Type I. ClinicalTrials.gov. (2009)."},{"key":"73_CR33","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nrc3911","volume":"15","author":"N Ratner","year":"2015","unstructured":"Ratner, N. & Miller, S. J. A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor. Nat. Rev. Cancer 15, 290\u2013301 (2015).","journal-title":"Nat. Rev. Cancer"},{"key":"73_CR34","doi-asserted-by":"crossref","first-page":"27012","DOI":"10.1016\/S0021-9258(19)74211-2","volume":"268","author":"JF Eccleston","year":"1993","unstructured":"Eccleston, J. F., Moore, K. J., Morgan, L., Skinner, R. H. & Lowe, P. N. Kinetics of interaction between normal and proline 12 Ras and the GTPase-activating proteins, p120-GAP and neurofibromin. The significance of the intrinsic GTPase rate in determining the transforming ability of ras. J. Biol. Chem. 268, 27012\u201327019 (1993).","journal-title":"J. Biol. Chem."},{"key":"73_CR35","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrc969","volume":"3","author":"J Downward","year":"2003","unstructured":"Downward, J. Targeting RAS signalling pathways in cancer therapy. Nat. Rev. Cancer 3, 11\u201322 (2003).","journal-title":"Nat. Rev. Cancer"},{"key":"73_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s40246-017-0109-3","volume":"1","author":"C Philpott","year":"2017","unstructured":"Philpott, C., Tovell, H., Frayling, I. M., Cooper, D. N. & Upadhyaya, M. The NF1 somatic mutational landscape in sporadic human cancers. Hum. Genomics 1, 13 (2017).","journal-title":"Hum. Genomics"},{"issue":"9","key":"73_CR37","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1038\/s41416-018-0046-5","volume":"118","author":"S. L. Scholz","year":"2018","unstructured":"Scholz, S. et al. NF1 mutations in conjunctival melanoma. Br. J. Cancer. (2018). https:\/\/doi.org\/10.1038\/s41416-018-0046-5 .","journal-title":"British Journal of Cancer"},{"key":"73_CR38","doi-asserted-by":"publisher","first-page":"e82","DOI":"10.1136\/jmg.40.6.e82","volume":"40","author":"E Ars","year":"2003","unstructured":"Ars, E. et al. Recurrent mutations in the NF1 gene are common among neurofibromatosis type 1 patients. J. Med. Genet. 40, e82 (2003).","journal-title":"J. Med. Genet."},{"key":"73_CR39","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1111\/cge.12187","volume":"85","author":"R Minkelen van","year":"2014","unstructured":"van Minkelen, R. et al. A clinical and genetic overview of 18\u2009years neurofibromatosis type 1 molecular diagnostics in the Netherlands. Clin. Genet. 85, 318\u2013327 (2014).","journal-title":"Clin. Genet."},{"key":"73_CR40","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1002\/humu.9429","volume":"27","author":"M Upadhyaya","year":"2006","unstructured":"Upadhyaya, M. et al. The heterogeneous nature of germline mutations in NF1 patients with malignant peripheral serve sheath tumours (MPNSTs). Hum. Mutat. 27, 716\u2013716 (2006).","journal-title":"Hum. Mutat."},{"key":"73_CR41","doi-asserted-by":"publisher","first-page":"E103","DOI":"10.1002\/humu.20793","volume":"29","author":"M Upadhyaya","year":"2008","unstructured":"Upadhyaya, M. et al. Germline and somatic NF1 gene mutations in plexiform neurofibromas. Hum. Mutat. 29, E103\u2013E111 (2008).","journal-title":"Hum. Mutat."},{"key":"73_CR42","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1002\/humu.9412","volume":"27","author":"M Raponi","year":"2006","unstructured":"Raponi, M., Upadhyaya, M. & Baralle, D. Functional splicing assay shows a pathogenic intronic mutation in neurofibromatosis type 1 (NF1) due to intronic sequence exonization. Hum. Mutat. 27, 294\u2013295 (2006).","journal-title":"Hum. Mutat."},{"key":"73_CR43","doi-asserted-by":"publisher","first-page":"E1506","DOI":"10.1002\/humu.21271","volume":"31","author":"E Pasmant","year":"2010","unstructured":"Pasmant, E. et al. NF1 microdeletions in neurofibromatosis type 1: from genotype to phenotype. Hum. Mutat. 31, E1506\u2013E1518 (2010).","journal-title":"Hum. Mutat."},{"key":"73_CR44","doi-asserted-by":"crossref","unstructured":"De Raedt, T. et al. Somatic loss of wild type NF1 allele in neurofibromas: comparison of NF1 microdeletion and non-microdeletion patients. Genes Chromosomes Cancer 45, 893\u2013904 (2006).","DOI":"10.1002\/gcc.20353"},{"key":"73_CR45","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1002\/ajmg.a.32045","volume":"146A","author":"H Kehrer-Sawatzki","year":"2008","unstructured":"Kehrer-Sawatzki, H., Schmid, E., F\u00fcnsterer, C., Kluwe, L. & Mautner, V.-F. Absence of cutaneous neurofibromas in an NF1 patient with an atypical deletion partially overlapping the common 1.4 Mb microdeleted region. Am. J. Med. Genet. A 146A, 691\u2013699 (2008).","journal-title":"Am. J. Med. Genet. A"},{"key":"73_CR46","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s00439-017-1766-y","volume":"136","author":"H Kehrer-Sawatzki","year":"2017","unstructured":"Kehrer-Sawatzki, H., Mautner, V.-F. & Cooper, D. N. Emerging genotype-phenotype relationships in patients with large NF1 deletions. Hum. Genet. 136, 349\u2013376 (2017).","journal-title":"Hum. Genet."},{"key":"73_CR47","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1136\/jmg.2009.075937","volume":"47","author":"VF Mautner","year":"2010","unstructured":"Mautner, V.-F. et al. Clinical characterisation of 29 neurofibromatosis type-1 patients with molecularly ascertained 1.4 Mb type-1 NF1 deletions. J. Med. Genet. 47, 623\u2013630 (2010).","journal-title":"J. Med. Genet."},{"key":"73_CR48","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1128\/MCB.00019-14","volume":"34","author":"MN Hinman","year":"2014","unstructured":"Hinman, M. N., Sharma, A., Luo, G. & Lou, H. Neurofibromatosis type 1 alternative splicing is a key regulator of Ras signaling in neurons. Mol. Cell Biol. 34, 2188\u20132197 (2014).","journal-title":"Mol. Cell Biol."},{"key":"73_CR49","doi-asserted-by":"publisher","first-page":"e53765","DOI":"10.1371\/journal.pone.0053765","volume":"8","author":"M Lenarduzzi","year":"2013","unstructured":"Lenarduzzi, M. et al. MicroRNA-193b enhances tumor progression via down regulation of neurofibromin 1. PLoS ONE 8, e53765 (2013).","journal-title":"PLoS ONE"},{"key":"73_CR50","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1101\/gad.1054703","volume":"17","author":"K Cichowski","year":"2003","unstructured":"Cichowski, K., Santiago, S., Jardim, M., Johnson, B. W. & Jacks, T. Dynamic regulation of the Ras pathway via proteolysis of the NF1 tumor suppressor. Genes Dev. 17, 449\u2013454 (2003).","journal-title":"Genes Dev."},{"key":"73_CR51","doi-asserted-by":"publisher","first-page":"5873","DOI":"10.18632\/oncotarget.2194","volume":"5","author":"YS Yap","year":"2014","unstructured":"Yap, Y.-S. et al. The NF1 gene revisited - from bench to bedside. Oncotarget 5, 5873\u20135892 (2014).","journal-title":"Oncotarget"},{"key":"73_CR52","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1038\/ejhg.2014.210","volume":"23","author":"D Emmerich","year":"2015","unstructured":"Emmerich, D. et al. Somatic neurofibromatosis type 1 (NF1) inactivation events in cutaneous neurofibromas of a single NF1 patient. Eur. J. Hum. Genet. 23, 870\u2013873 (2015).","journal-title":"Eur. J. Hum. Genet."},{"key":"73_CR53","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s10048-010-0240-y","volume":"11","author":"L Thomas","year":"2010","unstructured":"Thomas, L., Kluwe, L., Chuzhanova, N., Mautner, V. & Upadhyaya, M. Analysis of NF1 somatic mutations in cutaneous neurofibromas from patients with high tumor burden. Neurogenetics 11, 391\u2013400 (2010).","journal-title":"Neurogenetics"},{"key":"73_CR54","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/ejhg.2011.207","volume":"20","author":"L Thomas","year":"2012","unstructured":"Thomas, L. et al. Exploring the somatic NF1 mutational spectrum associated with NF1 cutaneous neurofibromas. Eur. J. Hum. Genet. 20, 411\u2013419 (2012).","journal-title":"Eur. J. Hum. Genet."},{"key":"73_CR55","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1086\/510781","volume":"80","author":"M Upadhyaya","year":"2007","unstructured":"Upadhyaya, M. et al. An absence of cutaneous neurofibromas associated with a 3-bp inframe deletion in exon 17 of the NF1 gene (c.2970-2972 delAAT): evidence of a clinically significant NF1 genotype-phenotype correlation. Am. J. Hum. Genet. 80, 140\u2013151 (2007).","journal-title":"Am. J. Hum. Genet."},{"key":"73_CR56","first-page":"1","volume":"23","author":"V Pinna","year":"2014","unstructured":"Pinna, V. et al. p.Arg1809Cys substitution in neurofibromin is associated with a distinctive NF1 phenotype without neurofibromas. Eur. J. Hum. Genet. 23, 1\u20134 (2014).","journal-title":"Eur. J. Hum. Genet."},{"key":"73_CR57","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1038\/ejhg.2015.93","volume":"23","author":"C Santoro","year":"2015","unstructured":"Santoro, C. et al. Arg(1809) substitution in neurofibromin: further evidence of a genotype-phenotype correlation in neurofibromatosis type 1. Eur. J. Hum. Genet. 23, 1460\u20131461 (2015).","journal-title":"Eur. J. Hum. Genet."},{"key":"73_CR58","doi-asserted-by":"publisher","first-page":"4714","DOI":"10.1038\/sj.onc.1210250","volume":"26","author":"H Saito","year":"2007","unstructured":"Saito, H., Yoshida, T., Yamazaki, H. & Suzuki, N. Conditional N-rasG12V expression promotes manifestations of neurofibromatosis in a mouse model. Oncogene 26, 4714\u20134719 (2007).","journal-title":"Oncogene"},{"key":"73_CR59","doi-asserted-by":"publisher","first-page":"30740","DOI":"10.1074\/jbc.M001702200","volume":"275","author":"LS Sherman","year":"2000","unstructured":"Sherman, L. S., Atit, R., Rosenbaum, T., Cox, A. D. & Ratner, N. Single cell Ras-GTP analysis reveals altered Ras activity in a subpopulation of neurofibroma Schwann cells but not fibroblasts. J. Biol. Chem. 275, 30740\u201330745 (2000).","journal-title":"J. Biol. Chem."},{"key":"73_CR60","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1001\/jama.2009.1663","volume":"302","author":"L Messiaen","year":"2009","unstructured":"Messiaen, L. et al. Clinical and mutational spectrum of neurofibromatosis type 1-like syndrome. JAMA 302, 2111 (2009).","journal-title":"JAMA"},{"key":"73_CR61","doi-asserted-by":"publisher","DOI":"10.1186\/s12864-017-3519-7","volume":"18","author":"GP Way","year":"2016","unstructured":"Way, G. P. et al. A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma. BMC Genomics 18, 127 (2016).","journal-title":"BMC Genomics"},{"issue":"6","key":"73_CR62","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/gim.2016.169","volume":"19","author":"Elizabeth J. Bhoj","year":"2016","unstructured":"Bhoj, E. J. et al. Phenotypic predictors and final diagnoses in patients referred for RASopathy testing by targeted next-generation sequencing. Genet. Med. 19, 715\u2013718 (2016).","journal-title":"Genetics in Medicine"},{"key":"73_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/sdata.2017.45","volume":"4","author":"SJC Gosline","year":"2017","unstructured":"Gosline, S. J. C. et al. A high-throughput molecular data resource for cutaneous neurofibromas. Sci. Data 4, 170045 (2017).","journal-title":"Sci. Data"},{"key":"73_CR64","doi-asserted-by":"publisher","first-page":"e0170348","DOI":"10.1371\/journal.pone.0170348","volume":"12","author":"DL Faden","year":"2017","unstructured":"Faden, D. L., Asthana, S., Tihan, T., De Risi, J. & Kliot, M. Whole exome sequencing of growing and non-growing cutaneous neurofibromas from a single patient with neurofibromatosis type 1. Gao J-X, editor. PLoS ONE 12, e0170348 (2017).","journal-title":"PLoS ONE"},{"key":"73_CR65","doi-asserted-by":"crossref","unstructured":"Anastasaki, C. et al. KIR2DL5 mutation and loss underlies sporadic dermal neurofibroma pathogenesis and growth. Oncotarget 8, 47574\u201347585 (2017).","DOI":"10.18632\/oncotarget.17736"},{"key":"73_CR66","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1158\/1078-0432.CCR-07-1305","volume":"14","author":"KK Mantripragada","year":"2008","unstructured":"Mantripragada, K. K. et al. High-resolution DNA copy number profiling of malignant peripheral nerve sheath tumors using targeted microarray-based comparative genomic hybridization. Clin. Cancer Res. 14, 1015\u20131024 (2008).","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"73_CR67","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1002\/gcc.20695","volume":"48","author":"Kiran K. Mantripragada","year":"2009","unstructured":"Mantripragada, K. K et al. Genome-wide high-resolution analysis of DNA copy number alterations in NF1-associated malignant peripheral nerve sheath tumors using 32K BAC array. Genes Chromosomes Cancer 48, 897\u2013907 (2009).","journal-title":"Genes, Chromosomes and Cancer"},{"key":"73_CR68","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1200\/JCO.2009.24.8989","volume":"28","author":"HR Brekke","year":"2010","unstructured":"Brekke, H. R. et al. Genomic changes in chromosomes 10, 16, and X in malignant peripheral nerve sheath tumors identify a high-risk patient group. J. Clin. Oncol. 28, 1573\u20131582 (2010).","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"73_CR69","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1002\/gcc.20921","volume":"50","author":"Eline Beert","year":"2011","unstructured":"Beert, E. et al. Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors. Genes Chromosomes Cancer 50,1021\u20131032 (2011).","journal-title":"Genes, Chromosomes and Cancer"},{"key":"73_CR70","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.gene.2014.12.064","volume":"558","author":"A Asai","year":"2015","unstructured":"Asai, A. et al. High-resolution 400K oligonucleotide array comparative genomic hybridization analysis of neurofibromatosis type 1-associated cutaneous neurofibromas. Gene 558, 220\u2013226 (2015).","journal-title":"Gene"},{"key":"73_CR71","unstructured":"Steensma, M. [NCT02777775] Targeting the Mechanisms Underlying Cutaneous Neurofibroma Formation in NF1: A Clinical Translational Approach. ClinicalTrials.gov. (2016)."},{"key":"73_CR72","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2164-14-473","volume":"14","author":"J Masliah-Planchon","year":"2013","unstructured":"Masliah-Planchon, J. et al. MicroRNAome profiling in benign and malignant neurofibromatosis type 1-associated nerve sheath tumors: evidences of PTEN pathway alterations in early NF1 tumorigenesis. BMC Genomics 14, 473 (2013).","journal-title":"BMC Genomics"},{"key":"73_CR73","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s00401-016-1540-6","volume":"131","author":"M R\u00f6hrich","year":"2016","unstructured":"R\u00f6hrich, M. et al. Methylation-based classification of benign and malignant peripheral nerve sheath tumors. Acta Neuropathol. 131, 877\u2013887 (2016).","journal-title":"Acta Neuropathol."},{"key":"73_CR74","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/nature13561","volume":"514","author":"T Raedt De","year":"2014","unstructured":"De Raedt, T. et al. PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies. Nature 514, 247\u2013251 (2014).","journal-title":"Nature"},{"key":"73_CR75","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1038\/ng.3095","volume":"46","author":"W Lee","year":"2014","unstructured":"Lee, W. et al. PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors. Nat. Genet. 46, 1227\u20131232 (2014).","journal-title":"Nat. Genet."},{"key":"73_CR76","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1016\/S1470-2045(12)70414-X","volume":"13","author":"KA Robertson","year":"2012","unstructured":"Robertson, K. A. et al. Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial. Lancet Oncol. 13, 1218\u20131224 (2012).","journal-title":"Lancet Oncol."},{"key":"73_CR77","doi-asserted-by":"publisher","first-page":"9","DOI":"10.12703\/P7-09","volume":"7","author":"TT Maciel","year":"2015","unstructured":"Maciel, T. T., Moura, I. C. & Hermine, O. The role of mast cells in cancers. F1000Prime Rep. 7, 9 (2015).","journal-title":"F1000Prime Rep."},{"key":"73_CR78","first-page":"323","volume":"23","author":"H Greggio","year":"1911","unstructured":"Greggio, H. Les cellules granuleuses (Mastzellen) dans les tissus normaux et dans certaines maladies chirurgicales. Arch. M\u00e9d. Exp. 23, 323\u2013375 (1911).","journal-title":"Arch. M\u00e9d. Exp."},{"key":"73_CR79","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1172\/JCI19195","volume":"112","author":"Y Feng-Chun","year":"2003","unstructured":"Feng-Chun, Y. et al. Neurofibromin-deficient Schwann cells secrete a potent migratory stimulus for Nf1+\/\u2013 mast cells. J. Clin. Invest. 112, 1851\u20131861 (2003).","journal-title":"J. Clin. Invest."},{"key":"73_CR80","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1172\/JCI200320503","volume":"112","author":"DH Viskochil","year":"2003","unstructured":"Viskochil, D. H. It takes two to tango: mast cell and Schwann cell interactions in neurofibromas. J. Clin. Invest. 112, 1791\u20131793 (2003).","journal-title":"J. Clin. Invest."},{"key":"73_CR81","first-page":"4713","volume":"35","author":"RE Friedrich","year":"2015","unstructured":"Friedrich, R. E., Naber, U., Glatzel, M. & Hagel, C. Vessel and mast cell densities in sporadic and syndrome-associated peripheral nerve sheath tumors. Anticancer Res. 35, 4713\u20134722 (2015).","journal-title":"Anticancer Res."},{"key":"73_CR82","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1097\/00000372-199402000-00008","volume":"16","author":"M Takata","year":"1994","unstructured":"Takata, M., Imai, T. & Hirone, T. Factor-XIIIa-positive cells in normal peripheral nerves and cutaneous neurofibromas of type-1 neurofibromatosis. Am. J. Dermatopathol. 16, 37\u201343 (1994).","journal-title":"Am. J. Dermatopathol."},{"key":"73_CR83","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s00401-012-1056-7","volume":"125","author":"CE Prada","year":"2013","unstructured":"Prada, C. E. et al. Neurofibroma-associated macrophages play roles in tumor growth and response to pharmacological inhibition. Acta Neuropathol. 125, 159\u2013168 (2013).","journal-title":"Acta Neuropathol."},{"key":"73_CR84","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nmeth.3337","volume":"12","author":"AM Newman","year":"2015","unstructured":"Newman, A. M. et al. Robust enumeration of cell subsets from tissue expression profiles. Nat. Methods 12, 1\u201310 (2015).","journal-title":"Nat. Methods"},{"key":"73_CR85","unstructured":"Li, B. et al. Comprehensive analyses of tumor immunity: implications for cancer immunotherapy. Genome Biol. 17, 174 (2016)."},{"key":"73_CR86","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1001\/jama.1936.02770090018005","volume":"106","author":"JC Sharpe","year":"1936","unstructured":"Sharpe, J. C. & Young, R. H. Neurofibromatosis: the effect of pregnancy on the skin manifestations. J. Am. Med. Assoc. 106, 682 (1936).","journal-title":"J. Am. Med. Assoc."},{"key":"73_CR87","doi-asserted-by":"publisher","first-page":"93","DOI":"10.4137\/CPath.S1002","volume":"1","author":"M Geller","year":"2008","unstructured":"Geller, M. et al. Progesterone and estrogen receptors in neurofibromas of patients with NF1. Clin. Med. Pathol. 1, 93\u201397 (2008).","journal-title":"Clin. Med. Pathol."},{"key":"73_CR88","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1002\/ajmg.a.35720","volume":"161","author":"C Cesaretti","year":"2013","unstructured":"Cesaretti, C. et al. Neurofibromatosis type 1 and pregnancy: maternal complications and attitudes about prenatal diagnosis. Am. J. Med. Genet. A. 161, 386\u2013388 (2013).","journal-title":"Am. J. Med. Genet. A."},{"key":"73_CR89","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1093\/oxfordjournals.aje.a010118","volume":"151","author":"SA Rasmussen","year":"2000","unstructured":"Rasmussen, S. A. & Friedman, J. M. NF1 gene and neurofibromatosis 1. Am. J. Epidemiol. 151, 33\u201340 (2000).","journal-title":"Am. J. Epidemiol."},{"key":"73_CR90","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1136\/jcp.56.10.758","volume":"56","author":"KSG Cunha","year":"2003","unstructured":"Cunha, K. S. G., Barboza, E. P. & Fonseca, E. C. Identification of growth hormone receptor in localized neurofibromas of patients with neurofibromatosis type 1. J. Clin. Pathol. 56, 758\u2013763 (2003).","journal-title":"J. Clin. Pathol."},{"key":"73_CR91","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1159\/000369802","volume":"83","author":"C Bizzarri","year":"2015","unstructured":"Bizzarri, C. & Bottaro, G. Endocrine implications of neurofibromatosis 1 in childhood. Horm. Res. Paediatr. 83, 232\u2013241 (2015).","journal-title":"Horm. Res. Paediatr."},{"key":"73_CR92","first-page":"70","volume":"53","author":"SJ Howell","year":"2000","unstructured":"Howell, S. J., Wilton, P., Lindberg, A. & Shalet, S. M. Growth hormone and neurofibromatosis. Horm. Res. 53, 70\u201376 (2000).","journal-title":"Horm. Res."},{"key":"73_CR93","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S0887-8994(00)00123-5","volume":"22","author":"R Vassilopoulou-Sellin","year":"2000","unstructured":"Vassilopoulou-Sellin, R., Klein, M. J. & Slopis, J. K. Growth hormone deficiency in children with neurofibromatosis type 1 without suprasellar lesions. Pediatr. Neurol. 22, 355\u2013358 (2000).","journal-title":"Pediatr. Neurol."},{"key":"73_CR94","first-page":"752","volume":"63","author":"ME McLaughlin","year":"2003","unstructured":"McLaughlin, M. E. & Jacks, T. Progesterone receptor expression in neurofibromas. Cancer Res. 63, 752\u2013755 (2003).","journal-title":"Cancer Res."},{"key":"73_CR95","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1203\/PDR.0b013e31817445b8","volume":"64","author":"A Overdiek","year":"2008","unstructured":"Overdiek, A., Winner, U., Mayatepek, E. & Rosenbaum, T. Schwann cells from human neurofibromas show increased proliferation rates under the influence of progesterone. Pediatr. Res. 64, 40\u201343 (2008).","journal-title":"Pediatr. Res."},{"key":"73_CR96","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/mc.20236","volume":"46","author":"L Fishbein","year":"2007","unstructured":"Fishbein, L. et al. In vitro studies of steroid hormones in neurofibromatosis 1 tumors and schwann cells. Mol. Carcinog. 46, 512\u2013523 (2007).","journal-title":"Mol. Carcinog."},{"key":"73_CR97","doi-asserted-by":"publisher","first-page":"758","DOI":"10.4161\/cbt.10.8.12878","volume":"10","author":"H Li","year":"2010","unstructured":"Li, H. et al. Analysis of steroid hormone effects on xenografted human NF1 tumor schwann cells. Cancer Biol. Ther. 10, 758\u2013764 (2010).","journal-title":"Cancer Biol. Ther."},{"issue":"16","key":"73_CR98","doi-asserted-by":"publisher","first-page":"3115","DOI":"10.1111\/febs.13798","volume":"283","author":"Dingxie Liu","year":"2016","unstructured":"Liu, D. Gene signa tures of estrogen and progesterone receptor pathways predict the prognosis of colorectal cancer. FEBS J. 283, 3115\u20133133 (2016).","journal-title":"The FEBS Journal"},{"key":"73_CR99","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s13555-012-0007-5","volume":"2","author":"YZ Chiang","year":"2012","unstructured":"Chiang, Y. Z., Al-Niaimi, F., Ferguson, J., August, P. J. & Madan, V. Carbon dioxide laser treatment of cutaneous neurofibromas. Dermatol. Ther. 2, 7 (2012).","journal-title":"Dermatol. Ther."},{"key":"73_CR100","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1007\/s10103-013-1469-0","volume":"29","author":"LK Kriechbaumer","year":"2014","unstructured":"Kriechbaumer, L. K., Susani, M., Kircher, S. G., Distelmaier, K. & Happak, W. Comparative study of CO2- and Er:YAG laser ablation of multiple cutaneous neurofibromas in von Recklinghausen\u2019s disease. Lasers Med. Sci. 29, 1083\u20131091 (2014).","journal-title":"Lasers Med. Sci."},{"key":"73_CR101","first-page":"1","volume":"2016","author":"DH Kim","year":"2016","unstructured":"Kim, D. H. et al. 27.12 MHz radiofrequency ablation for benign cutaneous lesions. Biomed. Res. Int. 2016, 1\u20136 (2016).","journal-title":"Biomed. Res. Int."},{"key":"73_CR102","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/j.bjps.2016.03.024","volume":"69","author":"CG Lutterodt","year":"2016","unstructured":"Lutterodt, C. G., Mohan, A. & Kirkpatrick, N. The use of electrodessication in the treatment of cutaneous neurofibromatosis: A retrospective patient satisfaction outcome assessment. J. Plast. Reconstr. Aesthetic Surg. 69, 765\u2013769 (2016).","journal-title":"J. Plast. Reconstr. Aesthetic Surg."},{"key":"73_CR103","doi-asserted-by":"publisher","first-page":"57","DOI":"10.5999\/aps.2013.40.1.57","volume":"40","author":"SH Kim","year":"2013","unstructured":"Kim, S.-H., Roh, S.-G., Lee, N.-H. & Yang, K.-M. Radiofrequency ablation and excision of multiple cutaneous lesions in neurofibromatosis type 1. Arch. Plast. Surg. 40, 57\u201361 (2013).","journal-title":"Arch. Plast. Surg."},{"key":"73_CR104","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1073\/pnas.0710355105","volume":"105","author":"DP Wermeling","year":"2008","unstructured":"Wermeling, D. P. et al. Microneedles permit transdermal delivery of a skin-impermeant medication to humans. Proc. Natl Acad. Sci. USA 105, 2058\u20132063 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"73_CR105","unstructured":"Massachusetts General Hospital. [NCT00865644] Topical Imiquimod 5% Cream for Treatment of Cutaneous Neurofibromas in Adults With Neurofibromatosis 1 No Title. ClinicalTrials.gov. (2009)."},{"key":"73_CR106","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1001\/archderm.1987.01660320053011","volume":"123","author":"VM Riccardi","year":"1987","unstructured":"Riccardi, V. M. Mast-cell stabilization to decrease neurofibroma growth. Prelim. Exp. ketotifen. Arch. Dermatol. 123, 1011\u20131016 (1987).","journal-title":"Prelim. Exp. ketotifen. Arch. Dermatol."},{"key":"73_CR107","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1001\/archderm.1993.01680260047004","volume":"129","author":"VM Riccardi","year":"1993","unstructured":"Riccardi, V. M. A controlled multiphase trial of ketotifen to minimize neurofibroma-associated pain and itching. Arch. Dermatol. 129, 577\u2013581 (1993).","journal-title":"Arch. Dermatol."},{"key":"73_CR108","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1002\/ajmg.a.37045","volume":"167","author":"VM Riccardi","year":"2015","unstructured":"Riccardi, V. M. Ketotifen suppression of NF1 neurofibroma growth over 30 years. Am. J. Med. Genet. A 167, 1570\u20131577 (2015).","journal-title":"Am. J. Med. Genet. A"},{"key":"73_CR109","unstructured":"Whelan, H. T. [NCT01682811] Photodynamic Therapy (PDT) for Benign Dermal Neurofibromas (NF1). ClinicalTrials.gov. (2012)."},{"key":"73_CR110","unstructured":"Whelan, H. T. [NCT02728388] Photodynamic Therapy for Benign Dermal Neurofibromas. ClinicalTrials.gov. (2016)."},{"key":"73_CR111","doi-asserted-by":"publisher","first-page":"975","DOI":"10.4236\/ijcm.2015.612128","volume":"6","author":"M Geller","year":"2015","unstructured":"Geller, M. et al. A proof-of-concept assessment of the safety and efficacy of intralesional diclofenac in the treatment of cutaneous neurofibromas. Int. J. Clin. Med. 6, 975\u2013983 (2015).","journal-title":"Int. J. Clin. Med."},{"key":"73_CR112","unstructured":"Funda\u00e7\u00e3o Educacional Serra dos \u00d3rg\u00e3os. [NCT03090971] Use of Topical Liquid Diclofenac Following Laser Microporation of Cutaneous Neurofibromas in Patients With NF1. ClinicalTrials.gov. (2017)."},{"key":"73_CR113","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1542\/peds.2007-3204","volume":"123","author":"VC Williams","year":"2009","unstructured":"Williams, V. C. et al. Neurofibromatosis type 1 revisited. Pediatrics 123, 124\u2013133 (2009).","journal-title":"Pediatrics"},{"key":"73_CR114","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1093\/bja\/86.4.555","volume":"86","author":"NP Hirsch","year":"2001","unstructured":"Hirsch, N. P., Murphy, A. & Radcliffe, J. J. Neurofibromatosis: clinical presentations and anaesthetic implications [Internet]. Br. J. Anaesth. 86, 555\u2013564 (2001).","journal-title":"Br. J. Anaesth."},{"key":"73_CR115","doi-asserted-by":"publisher","first-page":"8573","DOI":"10.1073\/pnas.0503224102","volume":"102","author":"CM Johannessen","year":"2005","unstructured":"Johannessen, C. M. et al. The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc. Natl Acad. Sci. USA 102, 8573\u20138578 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"73_CR116","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1056\/NEJMoa1605943","volume":"375","author":"E Dombi","year":"2016","unstructured":"Dombi, E. et al. Activity of selumetinib in neurofibromatosis type 1\u2013related plexiform neurofibromas. N. Engl. J. Med. 375, 2550\u20132560 (2016).","journal-title":"N. Engl. J. Med."},{"key":"73_CR117","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1111\/exd.12115","volume":"22","author":"Y Kawachi","year":"2013","unstructured":"Kawachi, Y. et al. NF1 gene silencing induces upregulation of vascular endothelial growth factor expression in both Schwann and non-Schwann cells. Exp. Dermatol. 22, 262\u2013265 (2013).","journal-title":"Exp. Dermatol."},{"key":"73_CR118","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.cell.2008.08.041","volume":"135","author":"FC Yang","year":"2008","unstructured":"Yang, F.-C. et al. Nf1-dependent tumors require a microenvironment containing Nf1+\/\u2212- and c-kit-dependent bone marrow. Cell 135, 437\u2013448 (2008).","journal-title":"Cell"},{"key":"73_CR119","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1034\/j.1600-0625.2003.00062.x","volume":"12","author":"Y Kawachi","year":"2003","unstructured":"Kawachi, Y., Xu, X., Ichikawa, E., Imakado, S. & Otsuka, F. Expression of angiogenic factors in neurofibromas. Exp. Dermatol. 12, 412\u2013417 (2003).","journal-title":"Exp. Dermatol."},{"key":"73_CR120","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s10585-008-9197-8","volume":"25","author":"J Wasa","year":"2008","unstructured":"Wasa, J. et al. Differential expression of angiogenic factors in peripheral nerve sheath tumors. Clin. Exp. Metastas. 25, 819\u2013825 (2008).","journal-title":"Clin. Exp. Metastas."},{"key":"73_CR121","unstructured":"Massachusetts General Hospital. [NCT00657202] Ranibizumab for Neurofibromas Associated With NF1. ClinicalTrials.gov. (2008)."},{"key":"73_CR122","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1093\/neuonc\/nou235","volume":"17","author":"B Weiss","year":"2014","unstructured":"Weiss, B. et al. Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a neurofibromatosis clinical trials consortium phase II study. Neuro. Oncol. 17, 596\u2013603 (2014).","journal-title":"Neuro. Oncol."},{"key":"73_CR123","doi-asserted-by":"publisher","first-page":"11053","DOI":"10.1200\/JCO.2016.34.15_suppl.11053","volume":"34","author":"BC Widemann","year":"2016","unstructured":"Widemann, B. C. et al. SARC016: phase II study of everolimus in combination with bevacizumab in sporadic and neurofibromatosis type 1 (NF1) related refractory malignant peripheral nerve sheath tumors (MPNST). J. Clin. Oncol. 34, 11053 (2016).","journal-title":"J. Clin. Oncol."},{"key":"73_CR124","unstructured":"The University of Texas Health Science Center - Houston. [NCT02332902] Everolimus for Treatment of Disfiguring Cutaneous Lesions in Neurofibromatosis1 CRAD001CUS232T (DCLNF1). ClinicalTrials.gov. (2014)."},{"key":"73_CR125","doi-asserted-by":"publisher","first-page":"53A","DOI":"10.1203\/00006450-199904020-00320","volume":"45","author":"DA Ingram","year":"1999","unstructured":"Ingram, D. A., Yang, F.-C., Travers, J. B. & Clapp, D. W. Nf1 modulates C-kit signaling in mast cells and neural crest derived melanocytes in vivo in a dose dependent fashion. Pediatr. Res. 45, 53A\u201353A (1999).","journal-title":"Pediatr. Res."},{"key":"73_CR126","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/bjd.13170","volume":"172","author":"I Khelifa","year":"2015","unstructured":"Khelifa, I., Saurat, J. H. & Prins, C. Use of imatinib in a patient with cutaneous vasculopathy in the context of von Recklinghausen disease\/neurofibromatosis. Br. J. Dermatol. 172, 253\u2013256 (2015).","journal-title":"Br. J. Dermatol."},{"key":"73_CR127","unstructured":"National Cancer Institute (NCI). [NCT01362803] AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors. ClinicalTrials.gov. (2011)."},{"key":"73_CR128","unstructured":"National Cancer Institute (NCI). [NCT02839720] Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Dermal Neurofibroma. ClinicalTrials.gov. (2016)."},{"key":"73_CR129","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1038\/ng.2396","volume":"44","author":"M Peifer","year":"2012","unstructured":"Peifer, M. et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat. Genet. 44, 1104\u20131110 (2012).","journal-title":"Nat. Genet."},{"key":"73_CR130","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/ng.2983","volume":"46","author":"K Wang","year":"2014","unstructured":"Wang, K. et al. Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer. Nat. Genet. 46, 573\u2013582 (2014).","journal-title":"Nat. Genet."},{"key":"73_CR131","doi-asserted-by":"publisher","first-page":"e1002223","DOI":"10.1371\/journal.pmed.1002223","volume":"14","author":"S Sivakumar","year":"2017","unstructured":"Sivakumar, S. et al. Master regulators of oncogenic KRAS response in pancreatic cancer: an integrative network biology analysis. PLoS Med. 14, e1002223 (2017).","journal-title":"PLoS Med."},{"key":"73_CR132","unstructured":"Assistance Publique - H\u00f4pitaux de Paris. [NCT01412892] Use of RAD001 as Monotherapy in the Treatment of Neurofibromatosis 1 Related Internal Plexiform Neurofibromas (NFitor). ClinicalTrials.gov. (2011)."},{"key":"73_CR133","unstructured":"The University of Texas Health Science Center - Houston. [NCT01031901] Topical Rapamycin Therapy to Alleviate Cutaneous Manifestations of Tuberous Sclerosis Complex (TSC) and Neurofibromatosis I (NF1). ClinicalTrials.gov. (2009)."}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41416-018-0073-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-018-0073-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-018-0073-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:02:14Z","timestamp":1684616534000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-018-0073-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,26]]},"references-count":133,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["73"],"URL":"https:\/\/doi.org\/10.1038\/s41416-018-0073-2","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,26]]},"assertion":[{"value":"18 August 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.L.R., P.K. and A.B. are employees of The Children\u2019s Tumor Foundation, which is a prominent non-profit funding organisation within the neurofibromatosis research community.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All patients provided consent for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"L.Q.L. holds a Career Award for Medical Scientists from the Burroughs Wellcome Fund, the Thomas L. Shield, M.D. Professorship in Dermatology and receives funding from the Giorgio Foundation, the National Cancer Institute of the NIH (grant number R01 CA166593), the Neurofibromatosis Therapeutic Acceleration Program and the NF1 Research Consortium Fund.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}}]}}